Home > Boards > US Listed > Medical - Healthcare > Mylan Inc. (MYL)

IIMO, It would be terrific if Mylan acquired

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Fortune 500 Member Profile
 
Followed By 0
Posts 98
Boards Moderated 0
Alias Born 12/17/18
160x600 placeholder
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Theravance Biopharma and Mylan Expand YUPELRI® (revefenacin) Development and Commercialization Agreement to Include China an... PR Newswire (US) - 6/14/2019 8:05:00 AM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/13/2019 12:59:29 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 6/7/2019 1:30:36 PM
Notice of Exempt Solicitation Pursuant to Rule 14a6(g) (px14a6n) Edgar (US Regulatory) - 5/31/2019 7:14:02 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/24/2019 5:13:35 PM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Theravance Biopharma and Mylan Present Additional YUPELRI® (revefenacin) Phase 3 Data Analysis at the 2019 ATS International... PR Newswire (US) - 5/20/2019 10:15:00 AM
Mylan Presents Equivalence and Device Usability Data on Wixela™ Inhub™ Compared to Advair Diskus® at American Thoracic S... PR Newswire (US) - 5/18/2019 10:45:00 AM
Mylan to Host Investor Day on July 31, 2019 in New York City PR Newswire (US) - 5/17/2019 8:00:00 AM
Mylan and Biocon to Present Final Overall Survival Data for Ogivri™ (trastuzumab-dkst), a biosimilar to Herceptin®, at the... PR Newswire (US) - 5/15/2019 5:01:00 PM
Mylan Expands Oncology Portfolio with Launch of Generic Tarceva® Tablets PR Newswire (US) - 5/10/2019 9:45:00 AM
Mylan to Present at the 2019 Bank of America Merrill Lynch Healthcare Conference PR Newswire (US) - 5/10/2019 8:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/10/2019 6:08:13 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/7/2019 11:07:10 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/7/2019 8:37:17 AM
Mylan Reports First Quarter 2019 Results and Reaffirms 2019 Guidance PR Newswire (US) - 5/7/2019 8:30:00 AM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2019 4:44:34 PM
Mylan to Release First Quarter 2019 Financial Results on May 7, 2019 PR Newswire (US) - 4/26/2019 7:30:00 AM
TB Alliance and Mylan Announce Global Collaboration to Commercialize Investigational Drug Pretomanid as Part of Two Regimens ... PR Newswire (US) - 4/18/2019 8:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/3/2019 6:02:46 PM
Striving to Create Better Health for a Better World: Mylan's Global Social Responsibility 2018 Progress Report Now Available PR Newswire (US) - 4/3/2019 11:00:00 AM
Mylan Institutional LLC Initiates Voluntary Nationwide Recall of Levoleucovorin Injection Due to the Presence of Particulate ... PR Newswire (US) - 3/18/2019 12:48:00 PM
SBP, Mylan Present Keys to Hurricane Maria Survivor in Welcome Home Party -- Courtesy of $1M Pledge from the Mylan Charitable... PR Newswire (US) - 3/7/2019 3:00:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 3/5/2019 6:35:12 PM
Fortune 500   Tuesday, 01/29/19 06:18:46 PM
Re: None
Post # of 141 
IIMO, It would be terrific if Mylan acquired a company such as Adxs so their students could be prepared for immunology . Mylan obviously can produce monoclonal antibody products . I expect we will see more biosimilars in the billions of dollars being approved this year as we saw in 2018. Since they are part of a Pittsburg school of pharmacy , it would be fitting for Mylan to grab a compsny like Adxs while it is vulnerable.
After all , Mylan’s slogan has always been .. quality is our blood line . It ‘s time to cure cancer . Let’s get to the next new thing now ! The moniclonals took way too long . Let’s get these immunological products on the market and then Mylan can be the acquirer . Let Teva make the epipen. Tired of reading about epipens. Necessary because we need immunotherapy! Organic chemicals are creating the allergens .

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist